Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma.

PubWeight™: 1.44‹?› | Rank: Top 5%

🔗 View Article (PMID 16628664)

Published in Hepatology on May 01, 2006

Authors

Mark Branda1, Jack R Wands

Author Affiliations

1: Liver Research Center, Department of Medicine, Rhode Island Hospital and Brown Medical School, Providence 02903, USA.

Articles citing this

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Viral hepatocarcinogenesis. Oncogene (2010) 1.73

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol (2010) 1.67

Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am (2010) 1.58

Molecular biology of liver cancer stem cells. Liver Cancer (2014) 1.41

Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39

Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33

Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther (2009) 1.31

Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer (2009) 1.28

Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One (2011) 1.27

Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci (2011) 1.16

Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol (2006) 1.12

Network-based pipeline for analyzing MS data: an application toward liver cancer. J Proteome Res (2011) 1.07

Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01

Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med (2014) 0.98

Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol (2012) 0.96

A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology (2014) 0.94

Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int (2013) 0.91

Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci (2008) 0.88

Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene (2011) 0.87

Liver cancer stem cells. Int J Hepatol (2011) 0.86

HBx-induced NF-κB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS One (2013) 0.85

Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PLoS One (2011) 0.83

RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-κB signaling via its novel chaperoning function. PLoS One (2011) 0.82

Targeting cancer stem cells by using the nanoparticles. Int J Nanomedicine (2015) 0.79

Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells Int (2016) 0.78

A new, effective and high-yield approach for identifying liver tumor suppressors. Genome Med (2009) 0.78

An Overview of Biomarkers and Molecular Signatures in HCC. Cancers (Basel) (2010) 0.77

Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma. Oncotarget (2016) 0.76

Identification of functional modules by integration of multiple data sources using a Bayesian network classifier. Circ Cardiovasc Genet (2014) 0.76

Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi. Am J Transl Res (2016) 0.75

Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol (2016) 0.75

Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci (2011) 0.75

Oldenlandia diffusa Promotes Antiproliferative and Apoptotic Effects in a Rat Hepatocellular Carcinoma with Liver Cirrhosis. Evid Based Complement Alternat Med (2015) 0.75

Articles by these authors

(truncated to the top 100)

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12

Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11

Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97

Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88

Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82

Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80

Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77

The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65

Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64

Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56

Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50

Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology (2006) 1.49

Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48

Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40

Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res (2004) 1.37

Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33

Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32

Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology (2007) 1.31

The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30

Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30

Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol (2008) 1.28

Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27

Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology (2003) 1.26

Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology (2004) 1.24

Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res (2007) 1.23

Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol (2006) 1.22

Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res (2007) 1.21

Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21

PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol (2009) 1.20

Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res (2006) 1.18

Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev (2010) 1.18

Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16

Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15

Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol (2004) 1.13

Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12

Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08

Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev (2012) 1.07

Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis (2009) 1.07

Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol (2010) 1.07

Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology (2006) 1.07

Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. Acta Neuropathol (2008) 1.06

Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology (2003) 1.06

Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology (2006) 1.04

Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol (2009) 1.04

Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol (2006) 1.04

Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology (2003) 1.03

Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02

Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev (2004) 1.01

Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01

Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology (2002) 1.01

The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00

Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol (2010) 0.99

Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss. Hum Pathol (2006) 0.99

Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98

Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98

Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97

Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. Am J Physiol Gastrointest Liver Physiol (2008) 0.96

The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun (2010) 0.96

Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol (2010) 0.94

Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res (2008) 0.94

ATP luminescence-based motility-invasion assay. Biotechniques (2002) 0.94

Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxid Med Cell Longev (2010) 0.94

Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis (2006) 0.94

Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract (2010) 0.94

Low density contrast agents for x-ray phase contrast imaging: the use of ambient air for x-ray angiography of excised murine liver tissue. Phys Med Biol (2008) 0.94

A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology (2014) 0.94

Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology (2006) 0.93

Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res (2011) 0.93

Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology (2009) 0.93

Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol (2006) 0.92

Nanomaterials for X-ray imaging: gold nanoparticle enhancement of X-ray scatter imaging of hepatocellular carcinoma. Nano Lett (2011) 0.92

Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int (2013) 0.91

Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91

Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol (2012) 0.91

Mechanisms of alcohol-induced tissue injury. Alcohol Clin Exp Res (2003) 0.91

Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology (2003) 0.91

Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol (2005) 0.90

Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol (2009) 0.90

Glycine decarboxylase mediates a postbinding step in duck hepatitis B virus infection. J Virol (2004) 0.89

Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-δ agonist treatment. J Gastroenterol Hepatol (2013) 0.89

Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp Cell Res (2011) 0.89

T1846 and A/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C. J Med Virol (2011) 0.89

Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas (2002) 0.88

Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. J Popul Ther Clin Pharmacol (2010) 0.88

Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol (2005) 0.88

High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res (2011) 0.88

Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 0.88

Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS One (2012) 0.86

Generation and characterization of an immunogenic dendritic cell population. J Immunol Methods (2008) 0.86

Angiogenic switch as a molecular target of malignant tumors. J Gastroenterol (2003) 0.86

Cytokine dependent and independent iNKT cell activation. Cytokine (2010) 0.86

Early growth response-1 transcription factor promotes hepatic fibrosis and steatosis in long-term ethanol-fed Long-Evans rats. Liver Int (2012) 0.85

Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res (2011) 0.84

Ethanol inhibits antigen presentation by dendritic cells. Clin Vaccine Immunol (2011) 0.84

Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology (2004) 0.84

Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther (2009) 0.84

Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. Hepatol Res (2013) 0.84